Hisao Imai1,2, Soichi Fumita3, Toshiyuki Harada4, Toshio Noriyuki5, Makio Gamoh6, Masaharu Okamoto7, Yusaku Akashi3, Yoshiyuki Kizawa8, Akihiro Tokoro9. 1. Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan. 2. Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan. 3. Department of Medical Oncology, Kindai University Nara Hospital, Ikoma, Japan. 4. Center for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan. 5. Department of Surgery, Onomichi General Hospital, Onomichi Japan. 6. Department of Medical Oncology, Osaki Citizen Hospital, Osaki, Japan. 7. Medical Affairs, Shionogi & Co., Ltd., Osaka, Japan. 8. Department of Palliative Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. 9. Department of Psychosomatic Internal Medicine and Supportive and Palliative Care Team, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.
Abstract
OBJECTIVE: To evaluate the opioid-induced constipation burden in the subgroup of patients with lung cancer who participated in the observational Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J) study. METHODS: The prospective, observational study, OIC-J, included 212 patients with various tumour types, 33% of whom had lung cancer. The incidence of opioid-induced constipation was evaluated using several diagnostic criteria, as well as the physician's diagnosis and patient's subjective assessment. Following initiation of opioids, patients recorded details of bowel movements (i.e. date/time, Bristol Stool Scale form, sensations of incomplete evacuation or anorectal obstruction/blockage and degree of straining) in a diary for 2 weeks. Relationships between patient characteristics and opioid-induced constipation onset and effects of opioid-induced constipation on quality of life were explored. RESULTS: In total, 69 patients were included in this post hoc analysis. The incidence of opioid-induced constipation varied (39.1-59.1%) depending on which diagnostic criteria was used. Diagnostic criteria that included a quality component or a patient's feeling of bowel movement as an evaluation item (i.e. Rome IV, physician's diagnosis, Bowel Function Index, patient's assessment) showed higher incidences of opioid-induced constipation than recording the number of spontaneous bowel movements alone. Opioid-induced constipation occurred rapidly after initiating opioids and had a significant impact on Patient Assessment of Constipation Symptoms total score (P = 0.0031). Patient baseline characteristics did not appear to be predictive of opioid-induced constipation onset. CONCLUSIONS: In patients with lung cancer, opioid-induced constipation can occur quickly after initiating opioids and can negatively impact quality of life. Early management of opioid-induced constipation, with a focus on quality-of-life improvement and patient's assessments of bowel movements, is important for these patients.
OBJECTIVE: To evaluate the opioid-induced constipation burden in the subgroup of patients with lung cancer who participated in the observational Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J) study. METHODS: The prospective, observational study, OIC-J, included 212 patients with various tumour types, 33% of whom had lung cancer. The incidence of opioid-induced constipation was evaluated using several diagnostic criteria, as well as the physician's diagnosis and patient's subjective assessment. Following initiation of opioids, patients recorded details of bowel movements (i.e. date/time, Bristol Stool Scale form, sensations of incomplete evacuation or anorectal obstruction/blockage and degree of straining) in a diary for 2 weeks. Relationships between patient characteristics and opioid-induced constipation onset and effects of opioid-induced constipation on quality of life were explored. RESULTS: In total, 69 patients were included in this post hoc analysis. The incidence of opioid-induced constipation varied (39.1-59.1%) depending on which diagnostic criteria was used. Diagnostic criteria that included a quality component or a patient's feeling of bowel movement as an evaluation item (i.e. Rome IV, physician's diagnosis, Bowel Function Index, patient's assessment) showed higher incidences of opioid-induced constipation than recording the number of spontaneous bowel movements alone. Opioid-induced constipation occurred rapidly after initiating opioids and had a significant impact on Patient Assessment of Constipation Symptoms total score (P = 0.0031). Patient baseline characteristics did not appear to be predictive of opioid-induced constipation onset. CONCLUSIONS: In patients with lung cancer, opioid-induced constipation can occur quickly after initiating opioids and can negatively impact quality of life. Early management of opioid-induced constipation, with a focus on quality-of-life improvement and patient's assessments of bowel movements, is important for these patients.
Authors: P J Larkin; N I Cherny; D La Carpia; M Guglielmo; C Ostgathe; F Scotté; C I Ripamonti Journal: Ann Oncol Date: 2018-10-01 Impact factor: 32.976
Authors: C Jara; S Del Barco; C Grávalos; S Hoyos; B Hernández; M Muñoz; T Quintanar; J A Meana; C Rodriguez; R de Las Peñas Journal: Clin Transl Oncol Date: 2017-11-10 Impact factor: 3.405
Authors: M Di Maio; C Gridelli; C Gallo; L Manzione; L Brancaccio; S Barbera; S F Robbiati; G P Ianniello; F Ferraù; E Piazza; L Frontini; F Rosetti; F Carrozza; A Bearz; M Spatafora; V Adamo; L Isa; R V Iaffaioli; E Di Salvo; F Perrone Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640